Easywell Biomedicals, Inc. (TPEX:1799)
Taiwan · Delayed Price · Currency is TWD 32.75
+0.75 (2.34%)
Feb 11, 2026, 1:30 PM CST
Easywell Biomedicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 588.89 | 540.44 | 271.63 | 178.9 | 197.28 | 267.65 | |
Revenue Growth (YoY) | 21.72% | 98.96% | 51.84% | -9.32% | -26.29% | -25.64% |
Cost of Revenue | 291.48 | 241.04 | 100.91 | 102.58 | 146.85 | 183.69 |
Gross Profit | 297.41 | 299.4 | 170.72 | 76.31 | 50.43 | 83.96 |
Selling, General & Admin | 103.75 | 94.88 | 61.96 | 28.16 | 24.15 | 21.21 |
Research & Development | 243.32 | 274.33 | 271.5 | 209.41 | 238.14 | 221.61 |
Operating Expenses | 347.86 | 374.19 | 333.46 | 237.57 | 262.29 | 242.82 |
Operating Income | -50.45 | -74.79 | -162.74 | -161.26 | -211.86 | -158.86 |
Interest Expense | -23.77 | -21.16 | -19.26 | -17.25 | -16.08 | -16.07 |
Interest & Investment Income | 2.52 | 4.94 | 3.42 | 2.18 | 1.18 | 0.4 |
Currency Exchange Gain (Loss) | -0.42 | 2.28 | 7.5 | 7.53 | -1.13 | -10.7 |
Other Non Operating Income (Expenses) | 9.04 | 0.34 | 1.17 | 0.46 | 57.99 | 0.92 |
EBT Excluding Unusual Items | -63.09 | -88.39 | -169.91 | -168.34 | -169.91 | -184.31 |
Gain (Loss) on Sale of Investments | 0.36 | 0.16 | - | 0.07 | 0.01 | - |
Gain (Loss) on Sale of Assets | 0.18 | 0.03 | - | - | 0.24 | 1.49 |
Other Unusual Items | - | -0.09 | - | - | - | - |
Pretax Income | -62.55 | -88.29 | -169.91 | -168.28 | -169.66 | -182.82 |
Income Tax Expense | 0.3 | 0.16 | 0.26 | 0.12 | 0.85 | 2.03 |
Earnings From Continuing Operations | -62.85 | -88.44 | -170.17 | -168.39 | -170.51 | -184.85 |
Net Income to Company | -62.85 | -88.44 | -170.17 | -168.39 | -170.51 | -184.85 |
Minority Interest in Earnings | -1.59 | -9.02 | 25.35 | 7.39 | 20.12 | 11.43 |
Net Income | -64.44 | -97.47 | -144.82 | -161 | -150.39 | -173.41 |
Net Income to Common | -64.44 | -97.47 | -144.82 | -161 | -150.39 | -173.41 |
Shares Outstanding (Basic) | 123 | 120 | 114 | 114 | 106 | 93 |
Shares Outstanding (Diluted) | 123 | 120 | 114 | 114 | 106 | 93 |
Shares Change (YoY) | 3.65% | 5.03% | 0.05% | 7.48% | 14.08% | 21.77% |
EPS (Basic) | -0.52 | -0.81 | -1.27 | -1.41 | -1.41 | -1.86 |
EPS (Diluted) | -0.52 | -0.81 | -1.27 | -1.41 | -1.41 | -1.86 |
Free Cash Flow | 12.01 | -171.53 | -169.17 | -60.99 | -136.02 | -174.83 |
Free Cash Flow Per Share | 0.10 | -1.43 | -1.48 | -0.53 | -1.28 | -1.88 |
Gross Margin | 50.50% | 55.40% | 62.85% | 42.66% | 25.56% | 31.37% |
Operating Margin | -8.57% | -13.84% | -59.91% | -90.14% | -107.39% | -59.35% |
Profit Margin | -10.94% | -18.04% | -53.31% | -90.00% | -76.23% | -64.79% |
Free Cash Flow Margin | 2.04% | -31.74% | -62.28% | -34.09% | -68.95% | -65.32% |
EBITDA | 9.44 | -22.19 | -121.01 | -116 | -160.42 | -96.31 |
EBITDA Margin | 1.60% | -4.11% | -44.55% | -64.84% | -81.32% | -35.98% |
D&A For EBITDA | 59.89 | 52.6 | 41.73 | 45.26 | 51.45 | 62.55 |
EBIT | -50.45 | -74.79 | -162.74 | -161.26 | -211.86 | -158.86 |
EBIT Margin | -8.57% | -13.84% | -59.91% | -90.14% | -107.39% | -59.35% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.